CDC Advisory Committee Recommends Booster Shot of Moderna's (MRNA) COVID-19 Vaccine

Moderna, Inc., (Nasdaq: MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines today announced that the U.S. Centers for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practices (ACIP) voted today to recommend the use of a booster dose of the Moderna COVID-19 vaccine at the 50 µg dose level for people aged 65 and older; people aged 18 to 64 who are at high risk of severe COVID-19; and people aged 18 to 64 with frequent institutional or occupational exposure to SARS-CoV-2 under the Emergency Use Authorization (EUA) issued yesterday by the U.S. Food and Drug Administration (FDA). The positive vote was unanimous with 15 ACIP members recommending the booster.

“Since we began this journey in January of 2020, our goal has been to protect as many people as possible from COVID-19. The ACIP recommendation is another step forward in our quest to address this devastating pandemic with a vaccine,” said Stéphane Bancel, Chief Executive Officer of Moderna. “We are grateful for the opportunity to provide individuals with another layer of protection against COVID-19.”

The ACIP is comprised of independent health experts. Today’s ACIP recommendation follows the FDA’s emergency use authorization for a booster dose, which was granted yesterday. This ACIP recommendation will be forwarded to the Director of the CDC and the U.S. Department of Health and Human Services (HHS) for review and adoption. The ACIP advises the CDC on the populations and circumstances for which vaccines should be used. The Committee based its recommendation on the totality of scientific evidence shared by the company and reviewed by the FDA’s Vaccines and Related Biological Products Advisory Committee (VRBPAC).

Moderna estimates that the authorization of a booster dose of mRNA-1273 at the 50 µg dose level and subsequent approval could result in up to 1 billion extra doses being available for distribution in 2022.

You May Also Be Interested In

• Mainz Biomed (MYNZ) Reports Positive Topline Results from Pooled Study Evaluating Novel mRNA Biomarkers and Proprietary AI Algorithm
• Moderna (MRNA) Collaborates with OpenAI
• AbbVie (ABBV): New Data Show RINVOQ Demonstrated Superiority Versus DUPIXENT Across Primary and All Secondary Endpoints